- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Redwood City Today
By the People, for the People
ARK Investment Management Sells Stake in Guardant Health
The investment firm reduced its holdings in the cancer diagnostics company by over 70%.
Published on Mar. 5, 2026
Got story updates? Submit your updates here. ›
ARK Investment Management LLC has significantly reduced its stake in Guardant Health, Inc. (NASDAQ:GH), selling 2,028,263 shares and cutting its position by 71.8% in the third quarter. The firm now owns 795,234 shares, or approximately 0.63% of the company's stock, valued at $49,686,000 at the end of the reporting period.
Why it matters
Guardant Health is a leading provider of liquid biopsy tests for cancer detection and monitoring. ARK Investment's decision to substantially reduce its position in the company could signal a shift in the firm's outlook on Guardant's prospects or the broader cancer diagnostics market.
The details
According to the filing, ARK Investment Management sold the 2,028,263 Guardant Health shares during the third quarter. This reduced the firm's total stake in the company to 795,234 shares, down from 2,823,497 shares held previously. The sale represented a 71.8% decrease in ARK's position in Guardant Health.
- ARK Investment Management filed the disclosure of its reduced stake in Guardant Health on March 5, 2026.
- The share sale occurred during the third quarter of the previous year.
The players
ARK Investment Management LLC
An investment management firm that focuses on disruptive innovation across multiple sectors, including healthcare and technology.
Guardant Health, Inc.
A precision oncology company that specializes in developing blood-based cancer diagnostics, including its flagship Guardant360 liquid biopsy test.
The takeaway
ARK Investment's significant reduction in its Guardant Health holdings could signal a shift in the firm's outlook on the cancer diagnostics market or the company's prospects. Investors will likely watch closely to see if other major institutional investors follow suit or maintain their positions in Guardant Health.
